Sign in
Enrolling by invitationPhase 4

Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients

Key facts

Who runs it
Ann & Robert H Lurie Children's Hospital of Chicago
Where
Chicago and Cincinnati, United StatesSee the 3 sites
Trial code
Status
Enrolling by invitation
Phase
Phase 4
People taking part
80 people, planned
Started
18 Mar 2024
Expected to end
30 Sept 2028
Type of study
Interventional
Treatments tested
  • Recombinant Zoster Vaccine
Record updated
27 March 2026

Who can take part

Age
19 years to 40 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • 19 years of age or older and willing to provide written informed consent for the study participation
  • Prior recipient of solid organ transplant more than one year prior to participation
  • Stable immunosuppressive medication regimen for last 6 months prior to participation
  • Participant must have a working telephone number, email address or patient Electronic Health Record (EHR) portal access and be willing to be contacted for study follow-up by any of these means
  • For participants of childbearing potential, use of effective pregnancy prevention till 2 months post last dose

Who cannot take part

  • Active treatment with corticosteroids or other immunosuppressive agents for acute or chronic rejection
  • More than 2 courses of treatment for acute rejection within last 2 years prior to study enrollment
  • History of anaphylaxis or other allergic reaction after receiving prior vaccinations or vaccine components
  • Receipt of any inactivated vaccine 8 days before/after dose #1, subunit vaccine 14 days before/after dose #1 and live, attenuated or mRNA vaccine 30 days before/after dose #1
  • History of herpes zoster, primary varicella or VZV vaccination within past 1 year prior to study entry
  • Active pregnancy as defined by positive pregnancy test at the time of screening and prior to each dose of vaccine
  • Febrile illness with Temp ≥39°C and/or infection that require hospitalization or oral antibiotics/antivirals/antifungal/anti-parasite medication within 14 days prior to day 1
  • Any condition that, in the opinion of the investigator, may interfere with optimal participation in the study

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 19 and 40 years old?

Where in United States

  • Ann & Robert H. Lurie Children's HospitalChicago, United StatesEnrolling by invitation
  • Northwestern Memorial HospitalChicago, United StatesEnrolling by invitation
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This goal of this study is to assess the safety and immunogenicity of recombinant zoster virus in young adult solid organ transplant recipients. In this study, participants will receive the recombinant zoster vaccine. They will be monitored for adverse events and tested for antibody and cellular immunity.

The group in the trial

  • Recombinant Zoster Vaccine Administration and TestingTreatment being tested

    all participants will receive 2 doses of recombinant zoster vaccine (Shingrix)

    Treatment: Recombinant Zoster Vaccine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06162494, who can take part
Record updated
27 March 2026